Abasaglar ® (basal insulin glargine)

This information is intended for UK registered healthcare professionals only as a scientific exchange in response to your search for information. Please refer to the link for full prescribing information: Abasaglar Summary of Product Characteristics (SmPC)

Abasaglar® (insulin glargine): Administration and Dosing Instructions

Proper administration and dosing of Abasaglar require adherence to specific instructions.

Administration Instructions

Insulin label must always be checked before each injection to avoid medication errors between Abasaglar and other insulins.1

The patient should be advised to read the instructions for use included in the package leaflet carefully before using Abasaglar.1  

Inspect Abasaglar before use. It must only be used if the solution is clear, colourless, with no solid particles visible, and if it is of water-like consistency. 1

Inject between 1 and 80 units of Abasaglar per injection.2

Abasaglar is administered subcutaneously into the abdominal area, deltoid or thigh.1

Injection sites should always be rotated within the same region in order to reduce the risk of lipodystrophy and cutaneous amyloidosis.1

Abasaglar must not be mixed with any other insulin or diluted. Mixing or diluting can change its time/action profile and mixing can cause precipitation.2

Abasaglar should not be administered intravenously.2

 

Dosing Instructions

In patients with T1DM, use Abasaglar concomitantly with mealtime insulin.3

In patients with T2DM, Abasaglar can also be given together with OAMs.1

Abasaglar should be administered once daily at any time but at the same time each day.1

The Abasaglar dose regimen (dose and timing) should be individually adjusted.1

 

Perform dosage adjustments of Abasaglar under medical supervision and with appropriate glucose monitoring.

Dosage adjustments may be needed with

  • changes in physical activity

  • changes in meal patterns

  • episodes of acute illness, or

  • changes in renal or hepatic function.1

References

1. Abasaglar [summary of product characteristics]. Eli Lilly Nederland B.V., The Netherlands.

2. Abasaglar [instructions for use]. Eli Lilly Nederland B.V., The Netherlands .

3. Data on file, Eli Lilly and Company and/or one of its subsidiaries.

Glossary

Abasaglar = Abasaglar® (insulin glargine) 100 units/mL

OAM = oral antihyperglycemic medication

T1DM = type 1 diabetes mellitus

T2DM = type 2 diabetes mellitus

Date of Last Review: July 22, 2019

Contact Lilly

Call or Email us

If you want to ask a Medical Information question or you want to report an adverse event or product complaint you can call us or email us at ukmedinfo@lilly.com

Available Mon - Fri, 8am - 4pm, excluding Bank Holidays

Or you can

Ask us a question Chat with Us If you have a question, you can chat online with a Lilly Medical Information professional.

Submit a question